Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea Initial distribution of Emrosi to p

Journey Medical Corporation Launches Emrosi

(40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Initial distribution of Emrosi to pharmacies

First prescriptions of Emrosi filled

Scottsdale, AZ - March 24, 2025 -

Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses

on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment

of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi (40 mg Minocycline Hydrochloride

Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in

adults. Emrosi is available by prescription at specialty pharmacy chains.

Claude Maraoui, Co-Founder,

President and Chief Executive Officer of Journey Medical, said, "We are thrilled that the initial distribution to pharmacies is

ongoing and the first Emrosi prescriptions have been filled. Rosacea is a challenging condition that affects millions, and Emrosi, the

lowest-dose oral minocycline on the market, delivers significantly superior clinical outcomes for rosacea compared to Oracea and

placebo, while maintaining a comparable safety profile, as demonstrated in clinical trials. The launch of Emrosi marks a major milestone

for Journey and underscores our commitment to improving the quality of life for those living with dermatology conditions such as rosacea."

The FDA approved Emrosi for the treatment of inflammatory

lesions of rosacea in adults in November 2024.

Important Safety Information

Indication: EMROSI is indicated

for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common

adverse reaction reported by 1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI

should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases

of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic

symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized,

discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years

may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated

Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should

be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia,

and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise.

Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while

using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs,

including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant

bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute

appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You

are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or

call 1-800-FDA-1088.

For full prescribing information, please visit

Rosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like

inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it

is estimated that rosacea affects over 16 million Americans and as many as 415 million people worldwide. Rosacea is most frequently

seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent

of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them

to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely

affected their professional interactions, and 51 percent said they had missed work because of their condition.

About Journey Medical Corporation

Journey Medical Corporation (Nasdaq: DERM) ("Journey

Medical") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription

pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently

markets eight branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry

experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands.

Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common

stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and

Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Forward-Looking Statements

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended. As used below and throughout this press release, the words "the Company", "we", "us"

and "our" may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth

strategy and product development programs and any other statements that are not historical facts. The words "anticipate,"

"believe," "estimate," "may," "expect," "will," "could," "project,"

"intend," "potential" and similar expressions are generally intended to identify forward-looking statements. Forward-looking

statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect

our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from

those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation

and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive

from products that are without patent protection and/or are, or may become, subject to third-party generic competition, the introduction

of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse

impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation

or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products

and any setback relating to the sale of such products could impair our operating results; competition could limit our products'

commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that

our products do not achieve broad market acceptance, including by government and third-party payors; our reliance on third parties for

several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate

them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance

our company and generate additional revenue, on the successful commercialization EmrosiTM and the successful development, regulatory

approval and commercialization of any future product candidates that we may develop, in-license or acquire; clinical drug development

is very expensive, time consuming, and uncertain and any clinical trials we may initiate for future product candidates may fail to adequately

demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products

similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient

patent protection for our technology and products; our business and operations would suffer in the event of computer system failures,

cyber-attacks, or deficiencies in our or our third parties' cybersecurity; the effects of major public health issues, epidemics

or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; the substantial doubt

expressed about our ability to continue as a going concern; Fortress controls a voting majority of our common stock, which could be detrimental

to our other stockholders; as well as other risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form

10-K for the year ended December 31, 2023, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim

any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect

any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may

be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities

Litigation Reform Act of 1995.

Media Relations Contact: